Mark Sheptoff Financial Planning LLC Buys New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 2,050 shares of the biotechnology company’s stock, valued at approximately $35,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Natixis Advisors LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter worth about $345,000. Mutual of America Capital Management LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at $701,000. Intech Investment Management LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at $1,242,000. Charles Schwab Investment Management Inc. increased its holdings in shares of ADMA Biologics by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company’s stock worth $48,007,000 after buying an additional 249,412 shares during the last quarter. Finally, Citigroup Inc. raised its position in shares of ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock worth $7,741,000 after buying an additional 277,138 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $20.22 on Wednesday. The firm’s fifty day simple moving average is $16.91 and its 200 day simple moving average is $18.10. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.64. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of 72.21 and a beta of 0.60.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.